Skip to main content

ORIGINAL RESEARCH article

Front. Immunol.
Sec. Autoimmune and Autoinflammatory Disorders: Autoinflammatory Disorders
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1383973
This article is part of the Research Topic Immunity and Inflammation in Neuropsychiatric Disorders View all 7 articles

IVIG response in Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) correlates with reduction in pro-inflammatory monocytes and neuropsychiatric measures

Provisionally accepted
Isaac R. Melamed Isaac R. Melamed 1*Shamma Rahman Shamma Rahman 2Heather Pein Heather Pein 1Melinda Heffron Melinda Heffron 1Jennifer Frankovich Jennifer Frankovich 2Huub Kreuwel Huub Kreuwel 3Elizabeth Mellins Elizabeth Mellins 2
  • 1 IMMUNOe Research Center, Centennial, Colorado, United States
  • 2 School of Medicine, Stanford University, Stanford, California, United States
  • 3 Octapharma USA, Paramus, New Jersey, United States

The final, formatted version of the article will be published soon.

    reports on new data exploring the link between inflammation in Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) and its improvement with IVIG treatment. Previous research has shown that IVIG infusions can correlate with reduced psychiatric symptoms. In this study we additionally evaluated pro-inflammatory myeloid cells (monocytes and dendritic cells), as well as clinical assessments including Tic and OCD scales over 18 weeks of treatment and at 1 and 8 weeks of post-treatment follow-up. The results strongly suggest an association of PANS with a proinflammatory state, which improves following treatment with IVIG.We believe these results are of clinical interest to the journal's readership, and of vital importance for the ongoing treatment and management of PANS. We are showing, for the first time, that IVIG treatment both reduces pro-inflammatory myeloid cell frequency and improves psychiatric symptoms scores. IVIG may therefore be a part of the clinical treatment path for patients with PANS, particularly those with severe and moderate disease, as included in this study.

    Keywords: Min.5-Max. 8): pediatric acute-onset neuropsychiatric syndrome, pans, Intravenous Immunoglobulin, IVIg, Autoimmune

    Received: 08 Feb 2024; Accepted: 06 Sep 2024.

    Copyright: © 2024 Melamed, Rahman, Pein, Heffron, Frankovich, Kreuwel and Mellins. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Isaac R. Melamed, IMMUNOe Research Center, Centennial, 80112, Colorado, United States

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.